Physician profile
Nahyoung Lee
NPI 1386898898
$5,197.75
in general payments reported to CMS, 2019-2025
7 companies · $552 in 2025
The $552 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $34.25 · 2021: $11.41 · 2022: $287 · 2023: $256 · 2024: $4,056 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,800 · Food and Beverage: $1,042 · Travel and Lodging: $23.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,800.00 |
| Food and Beverage | $1,042.17 |
| Travel and Lodging | $23.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,492.41 | 2024-2025 | Tepezza |
| Argenx US, INC. | $1,800.00 | 2024 | Vyvgart |
| Horizon Therapeutics Plc | $524.56 | 2020-2023 | Tepezza |
| Biotissue Holdings INC. | $187.60 | 2025 | |
| Bausch & Lomb Americas INC. | $128.76 | 2025 | Xiidra, Miebo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.42 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nahyoung Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.